New pancreatic cancer drug carries a $39,800 monthly list price: What to know - Yahoo Finance
The FDA has approved Rasonque, a new oral medication for metastatic pancreatic cancer that significantly improves survival rates. However, the drug carries a high list price of $477,000 per year, sparking discussions about patient affordability and insurance coverage.
Why it matters
It highlights the ongoing tension between medical innovation and the high cost of specialty pharmaceuticals in the U.S. healthcare system.
Personal Finance / Banking Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure .
New pancreatic cancer drug carries a $39,800 monthly list price: What to know Patients' out-of-pocket costs will vary based on insurance coverage and eligibility for financial assistance Hal Bundrick, CFP® · Senior Writer Fri, August 28, 2026 at 10:13 AM EDT 4 min read A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA.
Revolution Medicines' oral tablet daraxonrasib, branded as Rasonque, reduced the risk of death by 60% in phase 3 trials. Patients who received the medication in trials lived 13.2 months, compared with those on chemotherapy, who survived 6.7 months.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in